← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
elranatamab
L01FX32
Forms & Strengths
- Injection: 40 mg/mL solution in a single-dose vial
- Injection: 76 mg/mL solution in a single-dose vial
Adult Dosing
- Step-up dose 1: 12 mg SC on Day 1
- Step-up dose 2: 32 mg SC on Day 4
- First treatment dose: 76 mg SC on Day 8, then 76 mg SC once weekly through Week 24
- Maintenance: 76 mg SC every 2 weeks starting Week 25 in patients with a response
Pediatric Dosing
- Safety and efficacy have not been established in pediatric patients
Indications
- Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Mechanism of Action
- Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
- Binds to BCMA on multiple myeloma cells and CD3 on T-cells, bringing them together to activate T-cells, release inflammatory cytokines, and induce lysis of BCMA-expressing myeloma cells
Contraindications
- Known hypersensitivity to elranatamab or any of its excipients
Adverse Reactions
- Cytokine release syndrome (CRS)
- Neurologic toxicity, including Immune effector cell-associated neurotoxicity syndrome (ICANS)
- Severe infections and sepsis
- Neutropenia, anemia, and thrombocytopenia
- Fatigue, injection site reactions, musculoskeletal pain, and diarrhea
Drug Interactions
- Avoid concurrent use of live vaccines during treatment
- CYP450 substrates: Initiation of elranatamab causes release of cytokines that can suppress CYP450 enzymes; monitor for toxicity or altered efficacy of concomitantly administered drugs (e.g., warfarin, cyclosporine)
Curated Content: Needs Vetting Before Put to Clinical Use